CD8A and neoplasm: The combination of ACY-1215 and an anti-PD-L1 antibody improved the anti-tumor response in ARIDA-inactivated OCCCs by increasing the number of interferon γ (IFNγ)-positive cytotoxic CD8+ T cells [96].